1. Home
  2. ALLO vs TSBK Comparison

ALLO vs TSBK Comparison

Compare ALLO & TSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • TSBK
  • Stock Information
  • Founded
  • ALLO 2017
  • TSBK 1915
  • Country
  • ALLO United States
  • TSBK United States
  • Employees
  • ALLO N/A
  • TSBK N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • TSBK Banks
  • Sector
  • ALLO Health Care
  • TSBK Finance
  • Exchange
  • ALLO Nasdaq
  • TSBK Nasdaq
  • Market Cap
  • ALLO 277.8M
  • TSBK 248.8M
  • IPO Year
  • ALLO 2018
  • TSBK 1998
  • Fundamental
  • Price
  • ALLO $1.21
  • TSBK $32.39
  • Analyst Decision
  • ALLO Strong Buy
  • TSBK
  • Analyst Count
  • ALLO 9
  • TSBK 0
  • Target Price
  • ALLO $8.44
  • TSBK N/A
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • TSBK 12.3K
  • Earning Date
  • ALLO 08-06-2025
  • TSBK 07-22-2025
  • Dividend Yield
  • ALLO N/A
  • TSBK 3.21%
  • EPS Growth
  • ALLO N/A
  • TSBK 6.24
  • EPS
  • ALLO N/A
  • TSBK 3.25
  • Revenue
  • ALLO N/A
  • TSBK $76,813,000.00
  • Revenue This Year
  • ALLO N/A
  • TSBK N/A
  • Revenue Next Year
  • ALLO $199.63
  • TSBK N/A
  • P/E Ratio
  • ALLO N/A
  • TSBK $9.97
  • Revenue Growth
  • ALLO N/A
  • TSBK 2.71
  • 52 Week Low
  • ALLO $0.86
  • TSBK $24.81
  • 52 Week High
  • ALLO $3.78
  • TSBK $33.98
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 43.73
  • TSBK 56.09
  • Support Level
  • ALLO $1.11
  • TSBK $31.66
  • Resistance Level
  • ALLO $1.29
  • TSBK $32.25
  • Average True Range (ATR)
  • ALLO 0.09
  • TSBK 0.69
  • MACD
  • ALLO -0.01
  • TSBK 0.12
  • Stochastic Oscillator
  • ALLO 25.81
  • TSBK 75.98

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About TSBK Timberland Bancorp Inc.

Timberland Bancorp Inc is a bank holding company. It has one reportable operating segment which is defined as community banking in western Washington under the operating name Timberland Bank. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. It also offers loans to real estate, including residential and commercial, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.

Share on Social Networks: